Diffuse Astrocytic and Oligodendroglial Tumors in Adults
Key Points
Key Points
- Each year, more than 15,000 people in the United States are newly diagnosed with diffuse astrocytic and oligodendroglial tumors, including glioblastoma.
- Recently, several systemic agents and a device have demonstrated improvements in survival when added to surgical and radiation therapies.
- Genetic alterations, specifically Isocitrate Dehydrogenase 1 and 2 (IDH1 and IDH2), have become critical classification and prognostic biomarkers.
Treatment
...eatment...
...H-mutant Astrocytic and Oligodendroglial Tumors...
...ma, IDH-mutant, 1p/19q co-deleted, CNS WHO...
...ation 1.1People with oligodendroglioma...
...a reasonable alternative to PCV when to...
...ndation 1.2Within the group of people with o...
...endroglioma, IDH-mutant, 1p/19q co...
...mendation 1.3People with oligodendroglioma, IDH...
...mozolomide is a reasonable alternative to PCV wh...
...IDH-mutant, 1p/19q non-codeleted,...
...mendation 1.4People with astrocytoma, IDH...
...ion 1.5In astrocytoma, IDH-mutant, 1p/19q...
...H-mutant, 1p/19q non-codeleted, CNS WHO grade 2 (...
....6People with astrocytoma, IDH-mutant, 1p/19q n...
...H-mutant, CNS WHO grade 4 (former IDH...
...endation 1.7People with astrocytoma, IDH-mut...
...toma and Other IDH-wildtype Diffuse Glioma...
...ation 2.1People with astrocytomas, IDH-...
...ommendation 2.2Concurrent temozolomide...
...mmendation 2.3Six months of adjuvant temoz...
...mmendation 2.4Alternating electric field therap...
...dation 2.5Bevacizumab is NOT recommended for peop...
...dation 2.6In people with glioblastoma, IDH-wild...
....7In people with glioblastoma, IDH-wil...
...2.8No recommendation for or against any therapeu...
...e with recurrent glioblastoma should be r...
Recommendation 2.9No recommendation for or...
...e with diffuse midline glioma should be referred...
Table 1. Reasonable Doses and Schedules by Recommendation
...nable Doses and Schedules by RecommendationHavi...